6,7-Dimethoxyquinazoline-2,4-Dione Bulk Price Outlook for 2026
- Global bulk pricing for 6,7-dimethoxyquinazoline-2,4-dione is projected to stabilize in 2026 due to optimized synthesis routes and increased manufacturing capacity.
- Industrial purity (≥98%) and consistent COA documentation are critical for pharmaceutical intermediates used in APIs like alfuzosin.
- NINGBO INNO PHARMCHEM CO.,LTD. offers scalable supply (up to 20+ tons/year) with full technical support for B2B buyers.
As the pharmaceutical industry advances toward more efficient alpha-blocker therapies, demand for high-purity 6,7-dimethoxyquinazoline-2,4-dione (CAS 28888-44-0) continues to grow. This compound—also known as 6,7-dimethoxy-2,4(1H,3H)-quinazolinedione or 2,4-dihydroxy-6,7-dimethoxyquinazoline—serves as a pivotal building block in the synthesis of urological agents such as alfuzosin. With 2026 approaching, bulk procurement strategies must account for evolving market dynamics, raw material volatility, and stringent quality expectations.
Current Market Pricing Trends for Bulk Orders
Historical data from 2020–2025 indicates significant price dispersion across global suppliers, ranging from $6.68/kg to over $15.00/kg for technical-grade material. However, these figures often reflect small-batch or research-grade offerings lacking GMP-aligned documentation. In contrast, industrial-scale buyers seeking ≥98% purity with validated Certificates of Analysis (COA) now benefit from more competitive and transparent pricing structures.
By 2026, leading manufacturers have streamlined production through improved cyclization and methoxylation steps, reducing impurities and enhancing overall yield. This optimization directly impacts wholesale economics. For orders exceeding 1 kg, current indicative bulk prices hover between $8–$12 per kilogram, contingent on volume, packaging, and regulatory compliance requirements (e.g., DMF support, REACH registration).
When sourcing high-purity 6,7-Dimethoxyquinazoline-2,4-dione, buyers should prioritize suppliers with proven scale and analytical rigor—not just headline pricing.
Factors Influencing 2026 Wholesale Costs
Several technical and logistical variables shape the 2026 bulk price landscape for this quinazolinedione derivative:
- Synthesis Route Efficiency: Traditional methods involving anthranilic acid derivatives often suffer from low yields (<60%). Modern approaches using regioselective dimethoxylation followed by oxidative cyclization now achieve >85% isolated yield, lowering cost-per-kg.
- Purity & Specification Alignment: The compound’s identity as 6,7-dimethoxy-quinazoline-2,4-diol in tautomeric equilibrium necessitates rigorous HPLC and NMR validation. Suppliers offering ≥98% purity with residual solvent control (ICH Q3C) command premium reliability—and justified pricing.
- Supply Chain Resilience: Geopolitical shifts and logistics bottlenecks have pushed buyers toward vertically integrated manufacturers with in-house nitration, methylation, and crystallization capabilities.
- Regulatory Documentation: Full COA, MSDS, and batch-specific analytical reports (including LogP ≈ -0.49 and PSA = 84.18) are non-negotiable for API intermediates. Lack of documentation often masks hidden compliance costs.
Notably, the molecular formula C₁₀H₁₀N₂O₄ (MW: 222.197) and high melting point (~323°C) demand specialized handling during drying and milling to prevent decomposition—another factor influencing final unit cost.
How to Request Custom Quotations from Global Suppliers
B2B procurement of 6,7-dimethoxy-2,4-quinazolinedione in 2026 requires a structured request-for-quotation (RFQ) process that goes beyond simple price comparison. Buyers should specify:
- Required annual volume (e.g., 500 kg, 1 ton, 5+ tons)
- Purity threshold (typically ≥98% by HPLC)
- Packaging preferences (multi-layer HDPE drums, nitrogen-flushed bags)
- Need for regulatory support (GMP audit, DMF, TSE/BSE statement)
- Delivery timeline and Incoterms (FOB Shanghai, CIF Rotterdam, etc.)
Reputable manufacturers respond with itemized quotes that include stability data, storage guidance (cool, dry, ventilated conditions), and vapor pressure metrics (0.0 ± 1.4 mmHg at 25°C)—ensuring safe integration into downstream processes.
Why NINGBO INNO PHARMCHEM CO.,LTD. Stands Out in 2026
As a premier global manufacturer of complex heterocyclic intermediates, NINGBO INNO PHARMCHEM CO.,LTD. combines advanced process chemistry with industrial-scale infrastructure to deliver consistent, high-purity 6,7-dimethoxyquinazoline-2,4-dione. Their facility supports multi-ton annual output with real-time QC monitoring, ensuring every batch meets pharmacopeial standards for use in regulated API synthesis.
Key advantages include:
| Parameter | Specification |
|---|---|
| CAS Number | 28888-44-0 |
| Purity | ≥98% (HPLC) |
| Annual Supply Capacity | 20+ metric tons |
| Form | Brown crystalline powder |
| Storage | Sealed container, cool & dry, well-ventilated area |
| Documentation | Full COA, MSDS, HPLC chromatograms, synthetic route summary |
With a focus on sustainable manufacturing and client-specific customization, NINGBO INNO PHARMCHEM CO.,LTD. enables pharmaceutical developers to secure reliable, cost-effective access to this critical quinazolinedione scaffold—positioning them as a strategic partner for 2026 and beyond.